(Q34481479)

2 August 2017

1 reference

title

Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug (English)

1 reference

2 August 2017

Mitsiades N

1

1 reference

2 August 2017

Poulaki V

series ordinal

2

1 reference

2 August 2017

Mitsiades CS

series ordinal

3

1 reference

2 August 2017

Anderson KC

series ordinal

4

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

Expert Opinion on Investigational Drugs

2 August 2017

published in

1 reference

2 August 2017

volume

10

1 reference

2 August 2017

issue

6

1 reference

2 August 2017

page(s)

1075-1084

1 reference

Changing views of the role of matrix metalloproteinases in metastasis

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

Leukolysin/MMP25/MT6-MMP: a novel matrix metalloproteinase specifically expressed in the leukocyte lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

Regulation of matrilysin in the rat uterus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

Alpha 2-macroglobulin and tissue inhibitor of metalloproteinases: collagenase inhibitors in human preovulatory ovaries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

Tissue inhibitors of metalloproteinases: evolution, structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

Ongoing trials with matrix metalloproteinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

Purification and characterization of the Fas-ligand that induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

Monoclonal antibody-mediated tumor regression by induction of apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

Fas and Fas ligand interactions suppress melanoma lung metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

Development of inflammatory angiogenesis by local stimulation of Fas in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

Expression of Fas ligand in liver metastases of human colonic adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

Structural features and biochemical properties of TNF-alpha converting enzyme (TACE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

Downregulation of Fas ligand by shedding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

Fas-mediated apoptosis in seven human prostate cancer cell lines: correlation with tumor stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

Activation of the CD95 (APO-1/Fas) pathway in drug- and gamma-irradiation-induced apoptosis of brain tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

Induction of metalloproteinase activity in human T-lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1075

10.1517/13543784.10.6.1075

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference